Form D · Biotechnology
Xeno Biosciences Inc.
Cambridge, MA · CIK 0001748206
Offering snapshot reported Jan 5, 2023 · SEC filing
- Reported sold
- $1.5M Offering amount: $1.5M
- Investors reported
- 64 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 22, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 5, 2023 | Initial | $1,500,000 | No comparison | 64 | SEC filing |
| Aug 3, 2021 | Initial | $9,426,538 | No comparison | Not reported | SEC filing |
| Feb 8, 2019 | Initial | $720,000 | No comparison | 21 | SEC filing |
| Aug 3, 2018 | Initial | $450,000 | No comparison | 20 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-469839
Source: Form D, filed Jan 5, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey Arnold | Director |
| David Beno | Director, Executive |
| Hasan Celiker | Director, Executive |
| Tom Hughes | Director |
| Michael Koeris | Director |
| Stan Rose | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1770 Massachusetts Avenue, Suite 224
Cambridge, MA, 02140
Cambridge, MA, 02140